Immunofluorescence microscopy on the blood smear identifies patients with myeloproliferative neoplasms-Reference-Cited by-同舟云学术

Immunofluorescence microscopy on the blood smear identifies patients with myeloproliferative neoplasms

Published:2024-07-17 Issue:9 Volume:38 Page:2051-2058
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Zaninetti Carlo^ORCID,Vater Leonard,Kaderali Lars,Crodel Carl C.,Schnöder Tina M.,Fuhrmann Jessica,Swensson Leonard,Wesche Jan^ORCID,Freyer Carmen,Greinacher Andreas,Heidel Florian H.^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41375-024-02346-z.pdf

Reference13 articles.

1. Perner F, Perner C, Ernst T, Heidel FH. Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation. Cells. 2019;8:854.

2. Palandri F, Breccia M, Tiribelli M, Bonifacio M, Benevolo G, Iurlo A, et al. Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: real-world data. Hematol Oncol. 2020;38:372–80.

3. Palandri F, Rossi E, Auteri G, Breccia M, Paglia S, Benevolo G, et al. Predictors of response to hydroxyurea and switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: a real-world PV-NET study. Cancers. 2023;15:3706.

4. Verstovsek S, Krečak I, Heidel FH, De Stefano V, Bryan K, Zuurman MW, et al. Identifying patients with polycythemia vera at risk of thrombosis after hydroxyurea initiation: the polycythemia vera-advanced integrated models (PV-AIM) Project. Biomedicines. 2023;11:1925.

5. Palandri F, Palumbo GA, Bonifacio M, Elli EM, Tiribelli M, Auteri G, et al. A prognostic model to predict Ruxolitinib discontinuation and death in patients with myelofibrosis. Cancers. 2023;15:5027.